Nanus, David M.

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 3,645

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

Puca, L., Gavyert, K., Sailer, V., Conteduca, V., Dardenne, E., Sigouros, M., Isse, K., Kearney, M., Vosoughi, A., Fernandez, L., et al. (2019) · Science Translational Medicine

Prostate Cancer Treatment and ResearchLung Cancer Treatments and Mutations

Cited by 214

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591

Tagawa, S. T., Thomas, C., Sartor, A. O., Sun, M., Stangl-Kremser, J., Bissassar, M., Vallabhajosula, S., Castellanos, S. H., Nauseef, J. T., Sternberg, C. N., et al. (2024) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 78

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

Milowsky, M. I., Galsky, M. D., Morris, M. J., Crona, D. J., George, D. J., Dreicer, R., Tse, K., Petruck, J., Webb, I. J., Bander, N. H., et al. (2016) · Urologic Oncology: Seminars and Original Investigations

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 78

Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells

Zhu, J., Gong, J. Y., Goodman, O. B., Cartegni, L., Nanus, D. M., & Shen, R. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Prostate Cancer Treatment and ResearchRNA Research and Splicing

Cited by 47

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

Vlachostergios, P. J., Niaz, M. J., Sun, M., Mosallaie, S. A., Thomas, C., Christos, P. J., Osborne, J. R., Molina, A. M., Nanus, D. M., Bander, N. H., et al. (2021) · Frontiers in Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 43

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.

Tagawa, S. T., Sun, M. P., Nauseef, J. T., Thomas, C., Huicochea Castellanos, S., Thomas, J. E., Davidson, Z., Stangl-Kremser, J., Bissassar, M., Palmer, J., et al. (2023) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment

Cited by 11

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Tagawa, S. T., Osborne, J., Fernandez, E., Thomas, C., Niaz, M. J., Ciriaco, A., Vallabhajosula, S., Vlachostergios, P. J., Molina, A. M., Sternberg, C. N., et al. (2020) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 10